TY - JOUR
T1 - Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU
AU - Krag, Mette
AU - Marker, Søren
AU - Perner, Anders
AU - Wetterslev, Jørn
AU - Wise, Matt P
AU - Schefold, Joerg C
AU - Keus, Frederik
AU - Guttormsen, Anne B
AU - Bendel, Stepani
AU - Borthwick, Mark
AU - Lange, Theis
AU - Rasmussen, Bodil S
AU - Siegemund, Martin
AU - Bundgaard, Helle
AU - Elkmann, Thomas
AU - Jensen, Jacob V
AU - Nielsen, Rune D
AU - Liboriussen, Lisbeth
AU - Bestle, Morten H
AU - Elkjær, Jeanie M
AU - Palmqvist, Dorte F
AU - Bäcklund, Minna
AU - Laake, Jon H
AU - Bådstøløkken, Per M
AU - Grönlund, Juha
AU - Breum, Olena
AU - Walli, Akil
AU - Winding, Robert
AU - Iversen, Susanne
AU - Jarnvig, Inge-Lise
AU - White, Jonathan O
AU - Brand, Björn
AU - Madsen, Martin B
AU - Quist, Lars
AU - Thornberg, Klaus J
AU - Møller, Anders
AU - Wiis, Jørgen
AU - Granholm, Anders
AU - Anthon, Carl T
AU - Meyhoff, Tine S
AU - Hjortrup, Peter B
AU - Aagaard, Søren R
AU - Andreasen, Jo B
AU - Sørensen, Christina A
AU - Haure, Pernille
AU - Andersen, Karen L D
AU - Sølling, Christine
AU - Engstrøm, Janus
AU - Agerholm-Larsen, Birgit
AU - Møller, Morten H
AU - The SUP-ICU trial group
A2 - Møller, Kirsten
PY - 2018
Y1 - 2018
N2 - BACKGROUND: Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear.METHODS: In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary outcome was death by 90 days after randomization.RESULTS: A total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole group and 1653 to the placebo group. Data on the primary outcome were available for 3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 0.91 to 1.13; P=0.76). During the ICU stay, at least one clinically important event (a composite of clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection, or myocardial ischemia) had occurred in 21.9% of patients assigned to pantoprazole and 22.6% of those assigned to placebo (relative risk, 0.96; 95% CI, 0.83 to 1.11). In the pantoprazole group, 2.5% of patients had clinically important gastrointestinal bleeding, as compared with 4.2% in the placebo group. The number of patients with infections or serious adverse reactions and the percentage of days alive without life support within 90 days were similar in the two groups.CONCLUSIONS: Among adult patients in the ICU who were at risk for gastrointestinal bleeding, mortality at 90 days and the number of clinically important events were similar in those assigned to pantoprazole and those assigned to placebo. (Funded by Innovation Fund Denmark and others; SUP-ICU ClinicalTrials.gov number, NCT02467621 .).
AB - BACKGROUND: Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear.METHODS: In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary outcome was death by 90 days after randomization.RESULTS: A total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole group and 1653 to the placebo group. Data on the primary outcome were available for 3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 0.91 to 1.13; P=0.76). During the ICU stay, at least one clinically important event (a composite of clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection, or myocardial ischemia) had occurred in 21.9% of patients assigned to pantoprazole and 22.6% of those assigned to placebo (relative risk, 0.96; 95% CI, 0.83 to 1.11). In the pantoprazole group, 2.5% of patients had clinically important gastrointestinal bleeding, as compared with 4.2% in the placebo group. The number of patients with infections or serious adverse reactions and the percentage of days alive without life support within 90 days were similar in the two groups.CONCLUSIONS: Among adult patients in the ICU who were at risk for gastrointestinal bleeding, mortality at 90 days and the number of clinically important events were similar in those assigned to pantoprazole and those assigned to placebo. (Funded by Innovation Fund Denmark and others; SUP-ICU ClinicalTrials.gov number, NCT02467621 .).
U2 - 10.1056/NEJMoa1714919
DO - 10.1056/NEJMoa1714919
M3 - Journal article
C2 - 30354950
SN - 0028-4793
VL - 379
SP - 2199
EP - 2208
JO - The New England journal of medicine
JF - The New England journal of medicine
IS - 23
ER -